GTBP (GT Biopharma) Beginning Cash Position : $9.25 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is GT Biopharma Beginning Cash Position?

GT Biopharma's Beginning Cash Position for the quarter that ended in Sep. 2024 was $9.25 Mil.

GT Biopharma's quarterly Beginning Cash Position increased from Mar. 2024 ($1.08 Mil) to Jun. 2024 ($1.95 Mil) and increased from Jun. 2024 ($1.95 Mil) to Sep. 2024 ($9.25 Mil).

GT Biopharma's annual Beginning Cash Position increased from Dec. 2021 ($5.30 Mil) to Dec. 2022 ($8.97 Mil) but then declined from Dec. 2022 ($8.97 Mil) to Dec. 2023 ($5.67 Mil).

GT Biopharma Beginning Cash Position Historical Data

The historical data trend for GT Biopharma's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Beginning Cash Position Chart

GT Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

0.06

0.03

5.30

8.97

5.67

GT Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															2.77	2.65	1.08	1.95	9.25

GT Biopharma Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

GT Biopharma Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GT Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005

Website

https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Executives

Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen	director, officer: Exec. Chair. and Interim CEO	LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri	officer: CFO & Secretary	2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel	director	70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk	officer: Pres. of R&D, CMO	HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban	director	1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy	officer: Acting Chief Financial Officer	8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon	director, officer: CFO	7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross	director, officer: Chief Executive Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski	officer: Chief Medical Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith	director, 10 percent owner, officer: CEO	1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman	10 percent owner	224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc	10 percent owner
Bristol Investment Fund Ltd	10 percent owner	89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205